Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8209788 | 0.89 | ALDH1A1 (0.38) | HIF1APDE4BKMT2APTGS1PTGS2 | |
| SCHEMBL8213329 | 0.88 | PTGS1 (0.38) | PTGS1PTGS2ALDH1A1 | |
| SCHEMBL8209083 | 0.87 | PDE4B (0.38) | HIF1APDE4BMEN1KMT2APTGS1 | |
| SCHEMBL8211654 | 0.84 | PTGS1 (0.35) | HIF1AMEN1KMT2APTGS1PTGS2 | |
| SCHEMBL8201465 | 0.76 | HTR6 (0.43) | — | |
| SCHEMBL8208098 | 0.75 | HTR6 (0.48) | PDE4BCYP2D6 | |
| SCHEMBL8208559 | 0.75 | KMT2A (0.51) | MEN1KMT2AALDH1A1HPGDCYP2D6 | |
| SCHEMBL8201598 | 0.74 | AKR1C3 (0.46) | KMT2APTGS1 | |
| SCHEMBL8208544 | 0.73 | HTR6 (0.44) | MEN1KMT2A | |
| SCHEMBL8201984 | 0.73 | HTR6 (0.51) | PDE4BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6100291-A | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-08-08 | — | — | US | claimed |
| WO-1999047516-A1 | 3-(2-PYRROLIDINYLMETHYL)-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY | SLASSI ABDELMALIK (CA) | 1999-09-23 | — | — | WO | claimed |
| US-6100291-A | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-08-08 | — | — | US | disclosed |
| WO-1999047516-A1 | 3-(2-PYRROLIDINYLMETHYL)-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY | SLASSI ABDELMALIK (CA) | 1999-09-23 | — | — | WO | disclosed |